Bupropion-induced psychosis: Folklore or a fact? A systematic review of the literature

General Hospital Psychiatry

Volumn 33, Issue 6, 2011, Pages 612-617

  Kumar, Sanjeev ^a   Kodela, Sreekant ^a   Detweiler, Jonna G ^b   Kim, Kye Y ^a,b   Detweiler, Mark B ^a,b  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bupropion; Catatonia; Delirium; Dopamine; Psychosis

Indexed keywords

AMANTADINE; AMFEBUTAMONE; FLUOXETINE; HALOPERIDOL; LITHIUM SALT; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; PROPRANOLOL; QUETIAPINE; TIOTIXENE;

AGITATED DELIRIUM; AGITATION; ARTICLE; AUDITORY HALLUCINATION; BIPOLAR DEPRESSION; CATATONIA; CLINICAL TRIAL (TOPIC); DELIRIUM; DELUSION; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEAR; HALLUCINATION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MEDICAL HISTORY; MEDICAL LITERATURE; MORNING DOSAGE; ORGANIC PSYCHOSYNDROME; OUTCOME ASSESSMENT; PARANOIA; PARKINSONISM; PERCEPTION DISORDER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; VISUAL HALLUCINATION; VIVID DREAM; VULNERABLE POPULATION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOSES, SUBSTANCE-INDUCED; YOUNG ADULT;

EID: 82855175193     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2011.07.001     Document Type: Article

References (38)

1. Clayton AH, Gillespie EH. The American psychiatric publishing textbook of psychopharmacology, 4th ed. DOI: 10.1176/ appi.books. 9781585623860 Chapter 2.
2. Terry P., Katz J.L. Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology (Berl) 1997, 134(2):201-212.
3. Learned-Coughlin S.M., Bergström M., Savitcheva I., Ascher J., Schmith V.D., Långstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003, 54(8):800-805.
4. Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004, 6(4):159-166.
5. Dwoskin L.P., Rauhut A.S., King-Pospisil K.A., Bardo M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Reviews 2006, 12(3-4):178-207.
6. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000, 28(10):1176-1183.
7. Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009, 10(7):730-753.
8. Jefferson J.W., Pradko J.F., Muir K.T. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005, 27(11):1685-1695.
9. Post R.M., Altshuler L.L., Leverich G.S., Frye M.A., Nolen W.A., Kupka R.W., et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006, 189:124-131.
10. Goode D.J., Manning A.A. Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type. J Clin Psychiatry 1983, 44(7):253-255.
11. Hahn M., Hajek T., Alda M., Gorman J.M. Psychosis induced by low-dose bupropion: sensitization of dopaminergic system by past cocaine abuse?. J Psychiatr Pract 2007, 13(5):336-338.
12. Neumann M., Livak V., Paul H.W. Acute psychosis after administration of bupropion hydrochloride (Zyban). Psychiatr Prax 2004, 31(Suppl 1):S140-S141.
13. Seeman P., Weinshenker D., Quirion R., et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005, 102(9):3513-3518. 10.1073/pnas.0409766102.
14. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009, 35(3):549-562. 10.1093/schbul/sbp006.
15. McKetin R., McLaren J., Lubman D.I., Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006, 101(10):1473-1478.
16. Becker, Dufresne Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 1982, 139:1200-1201.
17. Johnston J.A., Lineberry C.G., Frieden C.S. Prevalence of psychosis, delusions, and hallucinations in clinical trials with bupropion. Am J Psychiatry 1986, 143(9):1192-1193.
18. Farooque M., Elliott J. Delayed psychosis induced by bupropion in a former cocaine abuser: a case report. Prim Care Companion J Clin Psychiatry 2010, 12(5). pii: PCC.09100943.
19. Liberzon I., Dequardo J.R., Silk K.R. Bupropion and delirium. Am J Psychiatry 1990, 147(12):1689-1690.
20. Van Putten T., Shaffer I. Delirium associated with bupropion. J Clin Psychopharmacol 1990, 10(3):234.
21. Jackson C.W., Head L.A., Kellner C.H. Catatonia associated with bupropion treatment. J Clin Psychiatry 1992, 53(6):210.
22. Fink M., Taylor M.A. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001, 251(Suppl 1):I8-I13.
23. Fink M., Taylor M. Catatonia: subtype or syndrome in DSM?. Am J Psychiatry 2006, 163:1875-1876.
24. Detweiler M.B., Mehra A., Rowell T., Kim K.Y., Bader G. Delirious mania and malignant catatonia: a report of 3 cases and review. Psychiatr Q 2009, 80(1):23-40. [Epub 2009 Feb 6].
25. Golden R.N., James S.P., Sherer M.A., Rudorfer M.V., Sack D.A., Potter W.Z. Psychoses associated with bupropion treatment. Am J Psychiatry 1985, 142(12):1459-1462.
26. Wang T.S., Shiah I.S., Yeh C.B., Chang C.C. Acute psychosis following sustained release bupropion overdose. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(1):149-151. [Epub 2004 23].
27. Golden R.N., Rudorfer M.V., Sherer M.A., Linnoila M., Potter W.Z. Bupropion in depression. I. Biochemical effects and clinical response. Arch Gen Psychiatry 1988, 45(2):139-143.
28. Golden R.N., De Vane C.L., Laizure S.C., Rudorfer M.V., Sherer M.A., Potter W.Z. Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 1988, 45(2):145-149.
29. Golden R.N. Diethylpropion, bupropion, and psychoses. Br J Psychiatry 1988, 153:265-266.
30. Englisch S., Inta D., Eer A., Zink M. Bupropion for depression in schizophrenia. Clin Neuropharmacol 2010, 33(5):257-259.
31. George T.P., Vessicchio J.C., Termine A., et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002, 52(1):53-61.
32. Javelot H., Baratta A., Weiner L., et al. Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge. Pharm World Sci 2009, 31(2):238-240. [Epub 2008 Nov 28].
33. Grover S., Das P.P. Can bupropion unmask psychosis. Indian J Psychiatry 2009 Jan, 51(1):53-54.
34. Bailey J., Waters S. Acute psychosis after bupropion treatment in a healthy 28-year-old woman. J Am Board Fam Med 2008, 21(3):244-245.
35. Howard W.T., Warnock J.K. Bupropion-induced psychosis. Am J Psychiatry 1999, 156(12):2017-2018.
36. Chan C.H., Liu H.C., Huang M.C. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. J Clin Psychopharmacol 2006, 26(6):677-679.
37. Dager S.R., Heritch A.J. A case of bupropion-associated delirium. J Clin Psychiatry 1990, 51(7):307-308.
38. Ames D., Wirshing W.C., Szuba M.P. Organic mental disorders associated with bupropion in three patients. J Clin Psychiatry 1992, 53(2):53-55.